

IFW



HERSHKOVITZ & ASSOCIATES
1725 I STREET N.W.
SUITE 300
WASHINGTON, DC 20006
703-323-9330

In re. Application of : Nicolae MANOLESCU et al Docket No.:P02250
Appln. No. : 10/567,842 Group Art Unit: Unknown
Filed : July 20, 2004 Examiner: Unknown
For : METHOD FOR IN VIVO DETERMINATION ON TESTED ANIMALS OF THE
EFFICIENT CONCENTRATION OF DEUTERIUM DEPLETED WATER FOR CANCER
THERAPY

COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

Transmitted herewith is **an IDS** in the above-captioned application.

Form PTO-1449

Copies of references cited

The fee has been calculated as shown below:

Claims After Amendment	No. of Claims Previously Paid	Present Extra	Small Entity		Large Entity	
			Rate	Fee	Rate	Fee
*Total Claims:			x 25=	\$ 0	x 50=	\$
**Indep. Claims:			x 100=	\$ 0	x 200=	\$
Multiple Dependent Claims Presented			+180=	\$	+360=	\$
Extension Fees for 1 Month			60	\$	120	\$
				\$		\$
			Total:	\$ 0	Total:	\$

* If less than 20, write 20

**If less than 3, write 3

Please charge my Deposit Account No. **50-2929** in the amount of \$.

A Check in the amount of \$ __ to cover the necessary fee is included.

The U.S. Patent and Trademark Office is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. **50-2929**:

Any additional filing fees required under 37 C.F.R. 1.16.

Any patent application processing fees under 37 C.F.R. 1.17, including any required extension of time fees in any concurrent or future reply requiring a petition for extension of time for its timely submission (37 CFR 1.136)(a)(3).

May 24, 2006

Date

Abraham Hershkovitz

Reg. No. 45,294

P02250.A04



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Nicolae MANOLESCU et al

Group Art Unit: Unknown

Appln. No. : 10/567,842

Examiner: Unknown

Filed : July 20, 2004

Confirmation No.: 7147

For : METHOD FOR IN VIVO DETERMINATION ON TESTED ANIMALS
OF THE EFFICIENT CONCENTRATION OF DEUTERIUM DEPLETED
WATER FOR CANCER THERAPY**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure set forth in 37 CFR 1.56 and in accordance with the provisions of 37 CFR 1.97 and 1.98, the following information is brought to the attention of the Examiner for consideration during examination of the instant application.

Applicant submits herewith a copy of the International Search Report (in English) mailed on February 28, 2005 and conducted in International Application No. PCT/RO2004/000012 of which the instant application is the U.S. National stage. In particular, the International Examiner cited:

- (1) Somlyai G et al: "The Biological Effects of Deuterium-Depleted Water, a Possible New Tool in Cancer Therapy";
- (2) WO 95/18545; this document is also cited beginning in paragraph [0003] of

P02250.A04

- the present application;
- (3) US 5,855,921 is cited beginning in paragraph [0009] of the present application;
 - (4) RO 112422 is cited beginning in paragraph [0002] of the present application;
 - (5) FR 2 552 324 is cited beginning in paragraph [0002] of the present application;
 - (6) PCT WO 96/33129 is cited beginning in paragraph [0002] of the present application;
 - (7) RU 2 182 562 is cited beginning in paragraph [0002] of the present application;
 - (8) US 5,788,953 is cited beginning in paragraph [0003] of the present application;
 - (9) WO 96/03996 is cited beginning in paragraph [0003] of the present application;
 - (10) Billingham, R.E. et al., 1953 nature, 172, 603 is cited beginning in paragraph [0005] of the present application;
 - (11) Miles, C.P., 1965, J Natl. cancer Inst. 34,103 is cited beginning in paragraph [0005] of the present application; and

P02250.A04

(12) Romanian Journal of Comparative Oncology, 4,295 is cited beginning in paragraph [0005] of the present application.

Copies of the above-listed documents (1), (2), (4)-(7), (9), (10) and (12) are enclosed herewith, as is a copy of the International Search Report and a completed copy of the PTO-1449 form listing these documents. Copies of documents (3) and (8) are not provided since they are U.S. patents readily available to the Examiner. A copy of document (11) is not yet available and will be provided as soon as it can be obtained. Accordingly, the Examiner is requested to consider these documents and to indicate such consideration by returning a signed and initialed copy of the PTO-1449 form as part of the next official communication.


Please charge any additional fees necessary for consideration of the papers filed herein and refund excess payments to Deposit Account No. 50-2929.

Questions related to this submission may be directed to the undersigned.

Respectfully submitted,
Nicolae MANOLESCU

May 24, 2006
HERSHKOVITZ & ASSOCIATES
1725 I STREET, N.W.
SUITE 300
WASHINGTON, DC 20006

(703) 323-9330
(703) 323-6617 (FAX)


Abraham Hershkovitz
Reg. No. 45,294



Substitute for form PTO-1449

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	P02250
-------	---	----	---	------------------------	--------

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
AA	US 5,788,953	08/04/1998	SOMLYAI		
AB	US 5,855,921	01/05/1999	SOMLYAI		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
BA	FR 2552324	03/29/1985	IONESCU			
BB	RO 112422	09/30/1997	STEFANESCU et al			
BC	RU 2182562	05/20/2002	SINJAK JU			
BD	WO 96/03996	02/15/1996	BAUER			
BE	WO 95/18545	07/13/1995	SOMLYAI			
BF	WO 9633129	10/24/1996	KOTAI			

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CA	Billingham, R.E. et al.	transplantation 2003, 76, 1409-1412	
CB	Miles, C.P., 1965, J Natl. cancer Inst. 34,103		
Comisel et al.	CCal	Romanian Journal of Comparative Oncology 2001, 295-299	
	CD	SOMLYAI et al: "The Biological Effects of Deuterium-Depleted Water, a Possible New Tool in Cancer Therapy" J. Oncol. 1998, 30, 91-94	

Examiner Signature	/Melissa Perreira/	Date Considered	09/28/2009
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.P./